Vijay Chaitanya Ganta1, Min Hyub Choi1, Anna Kutateladze1, Todd E Fox1, Charles R Farber1, Brian H Annex2. 1. From Cardiovascular Research Center (V.C.G., M.H.C., B.H.A.), Department of Biology (A.K.), Department of Pharmacology (T.E.F.), Department of Public Health Sciences (C.R.F.), and Department of Cardiology (B.H.A.), University of Virginia, Charlottesville. 2. From Cardiovascular Research Center (V.C.G., M.H.C., B.H.A.), Department of Biology (A.K.), Department of Pharmacology (T.E.F.), Department of Public Health Sciences (C.R.F.), and Department of Cardiology (B.H.A.), University of Virginia, Charlottesville. bh4an@virginia.edu.
Abstract
BACKGROUND: Currently, no therapies exist for treating and improving outcomes in patients with severe peripheral artery disease (PAD). MicroRNA93 (miR93) has been shown to favorably modulate angiogenesis and to reduce tissue loss in genetic PAD models. However, the cell-specific function, downstream mechanisms, or signaling involved in miR93-mediated ischemic muscle neovascularization is not clear. Macrophages were best known to modulate arteriogenic response in PAD, and the extent of arteriogenic response induced by macrophages is dependent on greater M2 to M1 activation/polarization state. In the present study, we identified a novel mechanism by which miR93 regulates macrophage polarization to promote angiogenesis and arteriogenesis to revascularize ischemic muscle in experimental PAD. METHODS: In vitro (macrophages, endothelial cells, skeletal muscle cells under normal and hypoxia serum starvation conditions) and in vivo experiments in preclinical PAD models (unilateral femoral artery ligation and resection) were conducted to examine the role of miR93-interferon regulatory factor-9-immunoresponsive gene-1 (IRG1)-itaconic acid pathway in macrophage polarization, angiogenesis, arteriogenesis, and perfusion recovery. RESULTS: In vivo, compared with wild-type controls, miR106b-93-25 cluster-deficient mice (miR106b-93-25-/-) showed decreased angiogenesis and arteriogenesis correlating with increased M1-like macrophages after experimental PAD. Intramuscular delivery of miR93 in miR106b-93-25-/- PAD mice increased angiogenesis, arteriogenesis, and the extent of perfusion, which correlated with more M2-like macrophages in the proximal and distal hind-limb muscles. In vitro, miR93 promotes and sustains M2-like polarization even under M1-like polarizing conditions (hypoxia serum starvation). Delivery of bone marrow-derived macrophages from miR106b-93-25-/- to wild-type ischemic muscle decreased angiogenesis, arteriogenesis, and perfusion, whereas transfer of wild-type macrophages to miR106b-93-25-/- had the opposite effect. Systematic analysis of top differentially upregulated genes from RNA sequencing between miR106b-93-25-/- and wild-type ischemic muscle showed that miR93 regulates IRG1 function to modulate itaconic acid production and macrophage polarization. The 3' untranslated region luciferase assays performed to determine whether IRG1 is a direct target of miR93 revealed that IRG1 is not an miR93 target but that interferon regulatory factor-9, which can regulate IRG1 expression, is an miR93 target. In vitro, increased expression of interferon regulatory factor-9 and IRG1 and itaconic acid treatment significantly decreased endothelial angiogenic potential. CONCLUSIONS: miR93 inhibits interferon regulatory factor-9 to decrease IRG1-itaconic acid production to induce M2-like polarization in ischemic muscle to enhance angiogenesis, arteriogenesis, and perfusion recovery in experimental PAD.
BACKGROUND: Currently, no therapies exist for treating and improving outcomes in patients with severe peripheral artery disease (PAD). MicroRNA93 (miR93) has been shown to favorably modulate angiogenesis and to reduce tissue loss in genetic PAD models. However, the cell-specific function, downstream mechanisms, or signaling involved in miR93-mediated ischemic muscle neovascularization is not clear. Macrophages were best known to modulate arteriogenic response in PAD, and the extent of arteriogenic response induced by macrophages is dependent on greater M2 to M1 activation/polarization state. In the present study, we identified a novel mechanism by which miR93 regulates macrophage polarization to promote angiogenesis and arteriogenesis to revascularize ischemic muscle in experimental PAD. METHODS: In vitro (macrophages, endothelial cells, skeletal muscle cells under normal and hypoxia serum starvation conditions) and in vivo experiments in preclinical PAD models (unilateral femoral artery ligation and resection) were conducted to examine the role of miR93-interferon regulatory factor-9-immunoresponsive gene-1 (IRG1)-itaconic acid pathway in macrophage polarization, angiogenesis, arteriogenesis, and perfusion recovery. RESULTS: In vivo, compared with wild-type controls, miR106b-93-25 cluster-deficient mice (miR106b-93-25-/-) showed decreased angiogenesis and arteriogenesis correlating with increased M1-like macrophages after experimental PAD. Intramuscular delivery of miR93 in miR106b-93-25-/- PAD mice increased angiogenesis, arteriogenesis, and the extent of perfusion, which correlated with more M2-like macrophages in the proximal and distal hind-limb muscles. In vitro, miR93 promotes and sustains M2-like polarization even under M1-like polarizing conditions (hypoxia serum starvation). Delivery of bone marrow-derived macrophages from miR106b-93-25-/- to wild-type ischemic muscle decreased angiogenesis, arteriogenesis, and perfusion, whereas transfer of wild-type macrophages to miR106b-93-25-/- had the opposite effect. Systematic analysis of top differentially upregulated genes from RNA sequencing between miR106b-93-25-/- and wild-type ischemic muscle showed that miR93 regulates IRG1 function to modulate itaconic acid production and macrophage polarization. The 3' untranslated region luciferase assays performed to determine whether IRG1 is a direct target of miR93 revealed that IRG1 is not an miR93 target but that interferon regulatory factor-9, which can regulate IRG1 expression, is an miR93 target. In vitro, increased expression of interferon regulatory factor-9 and IRG1 and itaconic acid treatment significantly decreased endothelial angiogenic potential. CONCLUSIONS:miR93 inhibits interferon regulatory factor-9 to decrease IRG1-itaconic acid production to induce M2-like polarization in ischemic muscle to enhance angiogenesis, arteriogenesis, and perfusion recovery in experimental PAD.
Authors: Sarah E J Chambers; Christina L O'Neill; T Michelle O'Doherty; Reinhold J Medina; Alan W Stitt Journal: Immunobiology Date: 2013-07-08 Impact factor: 3.144
Authors: Wilma Schierling; Kerstin Troidl; Christian Troidl; Thomas Schmitz-Rixen; Wolfgang Schaper; Inka K Eitenmüller Journal: J Vasc Res Date: 2009-01-10 Impact factor: 1.934
Authors: Alessandro Michelucci; Thekla Cordes; Jenny Ghelfi; Arnaud Pailot; Norbert Reiling; Oliver Goldmann; Tina Binz; André Wegner; Aravind Tallam; Antonio Rausell; Manuel Buttini; Carole L Linster; Eva Medina; Rudi Balling; Karsten Hiller Journal: Proc Natl Acad Sci U S A Date: 2013-04-22 Impact factor: 11.205
Authors: Li Li; Liping Huang; Sun-Sang J Sung; Amy L Vergis; Diane L Rosin; C Edward Rose; Peter I Lobo; Mark D Okusa Journal: Kidney Int Date: 2008-10-08 Impact factor: 10.612
Authors: Victoria Osinski; Prasad Srikakulapu; Young Min Haider; Melissa A Marshall; Vijay C Ganta; Brian H Annex; Coleen A McNamara Journal: Arterioscler Thromb Vasc Biol Date: 2021-11-23 Impact factor: 8.311
Authors: Christopher J Hall; Leslie E Sanderson; Lisa M Lawrence; Bregina Pool; Maarten van der Kroef; Elina Ashimbayeva; Denver Britto; Jacquie L Harper; Graham J Lieschke; Jonathan W Astin; Kathryn E Crosier; Nicola Dalbeth; Philip S Crosier Journal: J Clin Invest Date: 2018-03-26 Impact factor: 14.808